Heretic
Compound · Peptides

Thymosin alpha-1

Approved abroad for hepatitis and cancer support; the big sepsis trial came back null and the longevity story is extrapolation.

Updated 14 Oct 202610 sources9 min read
Short answer

Thymosin alpha-1 (thymalfasin, Zadaxin) is a 28-amino-acid thymic peptide approved in more than 35 countries for hepatitis B/C and as a cancer adjuvant, with a 2024 review covering over 11,000 subjects. The sepsis and longevity-clinic story is weaker: the largest randomized trial, TESTS (n=1,106), found no mortality benefit in sepsis, and a 2025 meta-analysis found earlier positive signals erode in high-quality trials. The live edge is oncology, where small studies position it as an immune-checkpoint-inhibitor adjunct.

Summary drafted from this entry’s sources; editorial review pending.

01Key questions

Is thymosin alpha-1 an approved drug?

Yes, in more than 35 countries for hepatitis B/C, melanoma adjuvant therapy and infections. In the US, compounded versions sit in FDA Category 2 after the December 2024 PCAC recommendation against 503A listing, so gray-market use carries heightened risk.1

Does thymosin alpha-1 help in sepsis?

Not overall. TESTS, a double-blind phase 3 trial in 1,106 patients, found no 28-day mortality benefit (23.4% vs 24.1%), and an updated 11-trial meta-analysis lost significance when restricted to high-quality multicentre studies. A possible benefit in older or chronic-disease subgroups remains unproven.35

Does thymosin alpha-1 slow immune aging?

Indirectly supported only. A 2025 review documents improved vaccine responses in the elderly and mitigation of immunosenescence markers, but direct longevity claims are extrapolated and observational rather than trial-tested.1

Does thymosin alpha-1 boost cancer immunotherapy?

Early signal. A 2026 review aggregated over 20 mostly small, single-centre datasets finding higher response rates and less checkpoint-inhibitor pneumonitis when T-alpha-1 was added, and a 2026 Cancer Research paper identified a miR-146a-5p/TLR7 mechanism in mice. Multicentre randomized trials are still missing.345

What would change this rating?

Results from the multicentre NSCLC consolidation trial completed in August 2026, publication of the irAE-rescue trial, and any study using miR-146a-5p as a prespecified biomarker.89

02Overview

Thymosin Alpha-1 (Tα1 / thymalfasin) is a 28-amino acid thymic peptide. FDA-approved (as Zadaxin in some contexts) and approved in 35+ countries for hepatitis B/C, melanoma adjuvant. Extensively studied for immunosenescence mitigation, vaccine response enhancement in elderly, and adjunct in infections/sepsis. Off-label use in longevity clinics for immune optimization.

03Human Evidence — Approved & Large Trials (Tier 2)

  • Approved indications: Chronic hepatitis B/C (strong data), melanoma adjuvant, various viral/bacterial infections. Used in >35 countries.
  • Comprehensive review (2024): >11,000 subjects across >30 trials; favorable safety/efficacy profile for approved uses (PMID 38308608).
  • Aging & immunosenescence (2025 review — primary source): Simonova MA et al. Aging and Thymosin Alpha-1. Int J Mol Sci. 2025;26(23):11470. doi 10.3390/ijms262311470. Preclinical + clinical data support improved vaccine response in elderly (influenza, COVID) and mitigation of immunosenescence via thymic output restoration, T-cell maturation, NK activity, Treg balance, and anti-inflammatory effects (↓ TNFα/IL-1β/IL-6, ↑ IL-10, Nrf-2 activation). Plasma Tα1 levels decline with age/inflammation.

Mechanistic highlights (human-relevant): - Enhances dendritic cell maturation, phagocytosis, HLA-DR/CD40/CD80/CD86. - Protects thymocytes from apoptosis; promotes IL-7 expression. - Antioxidant: neutralizes ROS, ↑ SOD, ↓ lipid peroxidation. - CNS/CV cross-effects: hypothalamic-pituitary modulation, ACE inhibition, anti-atherosclerotic signals in models.

04Sepsis Evidence — TESTS Phase 3 (Landmark 2025)

TESTS Trial — Wu J et al. BMJ 2025;388:e082583 (PMID 40447307; DOI 10.1136/bmj-2024-082583). - Design: Multicentre, double-blinded, randomised, placebo-controlled phase 3 — the largest Tα1 sepsis RCT to date. - Setting: 22 centres in China; enrolment Sep 2016 → Dec 2020. - n: 1,106 adults aged 18–85 with sepsis-3 diagnosis; 1:1 randomisation (Tα1 n=552 vs placebo n=554). Modified ITT analysis on 1,089 (Tα1=542, placebo=547). - Intervention: Subcutaneous Tα1 1.6 mg every 12 h × 7 days (or until ICU discharge/death/withdrawal). - Primary endpoint: 28-day all-cause mortality. - Primary result: 23.4% (127/542) Tα1 vs 24.1% (132/547) placebo — HR 0.99, 95% CI 0.77–1.27; p=0.93 (log-rank). No overall mortality benefit. - Secondary endpoints: No statistically significant differences (new infection, SOFA trajectory, ICU mortality, 90-day mortality, mHLA-DR recovery, Treg dynamics). - Safety: No difference in adverse events. - Pre-specified subgroup: Possible differential effect by age — HR 1.67 (95% CI 1.04–2.67) in <60 yr (signal toward harm) vs HR 0.81 (0.61–1.09) in ≥60 yr (numerical benefit). P-interaction = 0.04. - Author conclusion: TESTS does not support routine Tα1 use in unselected adult sepsis; future trials should target elderly + chronic-disease subgroups where signals exist.

Updated meta-analysis — Frontiers Cell Infect Microbiol Sep 2025 (PMID 40969554, DOI 10.3389/fcimb.2025.1673959): - Pooled 11 RCTs, n=1,927 (967 Tα1 / 960 control). - Overall: OR 0.73 (95% CI 0.59–0.90), p=0.003 — significant 28-day mortality reduction. - High-quality subgroup only: OR 0.82 (0.65–1.03), p=0.09 — non-significant. - Multicentre subgroup only: OR 0.86 (0.68–1.08), p=0.20 — non-significant. - Trial sequential analysis: required information size NOT reached → cumulative evidence at risk of false-positive; further trials needed. - Subgroup hints (low–moderate credibility per ICEMAN): possible benefit in cancer, diabetes, coronary heart disease subgroups. - Conclusion: signals of benefit erode as trial quality/multicentre status rises; personalised immunotherapy strategies needed.

Interpretation: The TESTS result effectively neutralised prior positive meta-analytic estimates. Earlier meta-analyses (Liu 2016 BMC Infect Dis, n=530) showing ~41% relative mortality reduction were underpowered and methodologically weaker. The 2025 evidence base shifts the burden of proof toward targeted-population trials; broad immunomodulation with Tα1 in undifferentiated sepsis is not supported.

COVID-19 / other infections: Improved T-cell recovery in lymphopenic patients; reduced mortality in severe cases in some studies; sustained IgG after vaccination in elderly.

Evidence separation (post-TESTS): - Strongest: Approved antiviral/oncology uses (human RCTs). - Moderate: Vaccine enhancement in elderly (clinical). - Emerging: Direct longevity/immunosenescence claims (extrapolated + observational). - Revised: Sepsis efficacy — broad claim downgraded; targeted subgroup signal retained but unproven.

05Preclinical / Mechanistic

  • Restores thymic function, enhances T-cell maturation and NK activity.
  • Reduces inflammatory markers; supports immune balance in aging models.
  • PANDA II trial protocol (Liu H et al., Future Cardiol 2025;21:447–454) extends Tα1 evaluation to immune modulation in acute aortic dissection surgery — a novel CV indication.

06Regulatory & Commercial Landscape

  • FDA: Approved for specific indications (Zadaxin); compounded versions subject to 503A/503B rules. Off-label longevity use is gray-area. | PCAC July 23–24, 2026: Tα1 was NOT among the seven peptides voted on for 503A inclusion (BPC-157, KPV, TB-500, MOTS-c, Emideltide, Epitalon, Semax). Tα1 was already reviewed at the PCAC December 4, 2024 meeting (alongside CJC-1295 and AOD-9604), where FDA proposed that both Tα1 (free base) and Tα1 acetate NOT be included on the 503A Bulks List, citing immunogenicity potential (aggregation, peptide-related impurities), absence of USP monograph, and inadequate characterization. Final rule status: as of October 2026, Tα1 remains on FDA Category 2 (significant safety risk) — compounding pharmacies continue to source under the 503A interim policy with heightened risk. This contrasts with the July 2026 seven investigational peptides that still have an open docket. |
  • Clinics: Marketed by Innovative Care, Javan Anti-Aging, 360MD Austin for immune optimization.
  • Claims audit: Cannot claim "reverses aging" or cure disease; permitted language limited to immune support in approved contexts.
  • Implication of TESTS: Sepsis-related marketing claims are no longer defensible based on current highest-quality evidence.

072025–2026 Update: Tα1 + Immune Checkpoint Inhibitor (ICI) Synergy, Novel Chaperone Mechanism, and Active Oncology Trials

The most clinically actionable 2025–2026 signal for Tα1 is its emergence as an ICI adjunct — particularly in NSCLC, melanoma, and colorectal cancer — driven by two converging lines of evidence: a novel mechanistic paper (Wei/Chen/Zhang, Cancer Research 2026) establishing Tα1 as a microRNA chaperone that licenses dendritic-cell-mediated antitumor immunity, and a comprehensive review (Frontiers in Immunology 2026) consolidating 20+ clinical datasets on Tα1+ICI combination therapy.

Novel mechanism: Tα1 as a microRNA chaperone (Cancer Research, June 2026)

Wei Y, Chen J, Zhang Y et al. Thymosin Alpha-1 Restores Chemotherapy-Induced Antitumor Immunity by Chaperoning a MicroRNA Ligand of TLR7 in Dendritic Cells. Cancer Res 2026;86(17):4238–4254. (Accepted June 10, 2026; revision April 16, 2026.)

  • Clinical observation: circulating Tα1 levels are reduced in patients after chemotherapy across multiple cancer types and in tumor-bearing mice.
  • Mechanism (in vitro + in vivo mice): 1. Chemotherapy-induced tumor apoptotic bodies (ABs) carry microRNAs including miR-146a-5p. 2. After DC phagocytosis of ABs, Tα1 binds and protects miR-146a-5p from lysosomal RNase A degradation in the endolysosomal compartment. 3. Preserved miR-146a-5p activates Toll-like receptor 7 (TLR7) in DCs → DC maturation, migration to tumor-draining lymph nodes, antigen presentation, and CD8⁺ T-cell priming. 4. Therapeutic Tα1 supplementation synergizes with chemotherapy to control established tumors in mice — only in tumors with high miR-146a-5p expression, and only in a TLR7-dependent manner (knockout mice lose the effect).
  • Significance: Tα1 is reframed as an endogenous miRNA chaperone that unlocks a previously rate-limiting step in DC licensing. This explains the empirical "chemo + Tα1 works better than chemo alone" pattern in older Chinese adjuvant trials and provides a biomarker (tumor miR-146a-5p) for patient selection.
  • Translational gap: the synergy was demonstrated in mice; no human chemo+Tα1 RCT with the miR-146a-5p/TLR7 mechanism as the prespecified biomarker has been published. Tier: preclinical mechanistic breakthrough; human validation pending.

Tα1 + ICI clinical review (Frontiers in Immunology, 2026)

Frontiers Immunology 2026 — "Thymosin α1 combined with immune checkpoint inhibitors: synergistic remodeling of the tumor immune microenvironment." (Open-access, 2026.)

A 2026 narrative/systematic review aggregates >20 clinical datasets on Tα1 combined with PD-1/PD-L1 inhibitors (tislelizumab, nivolumab, toripalimab, pembrolizumab) across NSCLC, melanoma, colorectal cancer, and late-stage refractory solid tumors. Key findings:

Study / design n Indication Regimen Result Safety
Zhang et al. (single-arm Ph2) 20 Locally advanced CRC Tα1 4.8 mg 2×/wk × 11 wk + tislelizumab + neoadjuvant chemoradiation ORR 85% (CR 40%, PR 45%); DCR 100%; EFS 100% at median 10 mo Only 1 grade 3 AE; rest grade 1–2
Zhang & Zhou et al. (single-arm) 9 Stage IV melanoma, elderly, ECOG ≥2 ORR 22.2%, DCR 77.8%, mPFS 8.2 mo, mOS not reached at 9.9 mo All grade 1 (vitiligo, transaminitis)
Zhang et al. (double-arm) 48 / 101 / 47 Locally advanced NSCLC (CCRT + nivolumab ± Tα1) Tα1 1.6 mg qw PFS 14.6 vs 16.0 vs NR mo, p=0.03; OS 20.0 vs 27.6 vs NR mo, p=0.01; grade ≥2 pneumonitis 14.5% vs 35.4% (p=0.02) Tα1 reduced irAE pneumonitis + lymphopenia
Single-arm 21 Late-stage refractory solid tumors Tα1 + PD-1/PD-L1 + radiotherapy + GM-CSF ORR 23.8%, DCR 47.6% No grade ≥3

Swipe table →

Mechanistic rationale (per review): Tα1 enhances immune competence while selectively suppressing excessive activation outside the tumor microenvironment — i.e., it shifts the immune setpoint toward tumor-specific killing while dampening ICI-induced autoimmune toxicity. The decreased pneumonitis rate (14.5% vs 35.4%) in the NSCLC CCRT-nivolumab dataset is a notable irAE-mitigation signal.

Limitations explicitly acknowledged by the authors: - Predominantly single-center, small-sample trials; external validity uncertain. - No dose-finding studies; 1.6 mg vs 4.8 mg, 2×/wk vs 3×/wk vs daily, treatment duration all remain unoptimized. - High cost of Tα1 (~$150–$400 per 1.6 mg vial in the US) — no published cost-effectiveness vs irAE management costs. - Tier: 2 (early clinical signal; awaiting multicenter RCT). Author conclusion: "Large-scale, multi-center clinical trials are urgently needed."

Active 2025–2026 oncology trials (ClinicalTrials.gov)

Trial Phase Design Status Notes
NCT06139419 (Sun Yat-sen, China) 2 biweekly during CCRT; Q3W during consolidation × 12 mo) Active, not recruiting; completed Aug 30, 2026 n=114. Primary: completion rate of IO consolidation. 2-yr OS, 1-yr PFS, ≥grade 2 pneumonia
NCT06607926 2/3 (Ph2 portion) Recruiting Multi-center RCT; primary pathologic response rate
NCT06178146 (Jun Wang, China) 4 (post-marketing) Tα1 1.6 mg for ICI-induced irAEs vs conventional immunosuppression Completed April 2025; status "Unknown" (awaiting publication) n=40. Tests Tα1 as irAE rescue therapy

Swipe table →

Implications for evidence tier

The 2025–2026 Tα1 evidence base has expanded upward in oncology (from "approved antiviral/oncology adjuvant" to "rational ICI combination partner with mechanistic biomarker") while remaining stable-to-downgraded in non-oncology indications: - Upgraded: Tα1 + ICI in geriatric oncology (well-defined biological rationale, multiple Phase 2 signals, plausible biomarker miR-146a-5p). - Stable: approved antiviral/melanoma adjuvant uses; vaccine enhancement in elderly. - Downgraded (post-TESTS): undifferentiated sepsis; broad "immune booster" longevity claims. - New investigational: irAE management (NCT06178146).

Open questions

  • Does the miR-146a-5p/TLR7 chaperone mechanism explain the better performance in elderly patients (TESTS subgroup signal) or in NSCLC CCRT-pneumonitis datasets?
  • Will the Sun Yat-sen NCT06139419 (results expected late 2026 / early 2027) confirm the NSCLC CCRT-IO consolidation signal?
  • Will NCT06178146 (irAE management) publish in 2026, validating Tα1 as an irAE rescue rather than a primary oncology agent?

Key 2025–2026 sources added

  • Wei Y et al. Cancer Res 2026;86(17):4238–4254 — Tα1 as miR-146a-5p chaperone → TLR7 licensing in DCs
  • Frontiers Immunology 2026 — Tα1 + ICI synergy review (open-access)
  • ClinicalTrials.gov NCT06139419 — Sun Yat-sen NSCLC, Tα1 4.8 mg + tislelizumab consolidation, completed Aug 2026
  • ClinicalTrials.gov NCT06607926 — neoadjuvant NSCLC, Tα1 4.8 mg 2×/wk × 12 wk
  • ClinicalTrials.gov NCT06178146 — Tα1 for ICI-induced irAEs, completed Apr 2025
  • ClinicalTrials.gov NCT06821100 — Methodist Hospital, Tα1 + COVID-19 vaccine booster in adults 65–100, recruiting through Dec 2026
  • FDA PCAC Dec 4, 2024 briefing (FDA-2024-N-3534-0470) — Tα1 evaluation; FDA proposed NOT to include on 503A Bulks List (immunogenicity + characterization concerns)
  • FDA Category 2 list — Tα1 remains on Category 2 for compounded injectable use (potential immunogenicity, peptide-related impurities)

Updated 2026-10-04. No therapeutic advice. Verify all clinical-trial status on ClinicalTrials.gov before citing.

08Where to get it

No links for this entry

Thymosin alpha-1 is sold mainly through gray-market vendors whose products are not independently tested. We don't link to sellers of compounds like this, affiliate or otherwise. How we make money

09Connections

Neighborhood · 1 linked entryOpen full map →
Hallmarks of agingMechanism · 17 links→

10Sources

  1. PMID 38308608 (2024) — Comprehensive safety/efficacy review (>11k subjects)PubMed 38308608
  2. DOI 10.3390/ijms262311470DOI 10.3390/ijms262311470
  3. Wu J et al. (2025) BMJ 388:e082583 — TESTS Phase 3 RCT (n=1,106) — PMID 40447307 — landmark negative trial, now anchors sepsis evidencePubMed 40447307
  4. DOI 10.1136/bmj-2024-082583DOI 10.1136/bmj-2024-082583
  5. Frontiers Cell Infect Microbiol (Sep 2025) — PMID 40969554 — updated 11-RCT meta-analysis with TSA; signals weaker in high-quality trialsPubMed 40969554
  6. DOI 10.3389/fcimb.2025.1673959DOI 10.3389/fcimb.2025.1673959
  7. ClinicalTrials.gov (sepsis NCT02867267 , hepatitis, COVID trials; ongoing NCT06821100 for vaccine enhancement)NCT02867267 · NCT06821100
  8. NCT06139419NCT06139419
  9. NCT06607926NCT06607926
  10. NCT06178146NCT06178146

11Entry history

Latest content update.

Heretic informs and never prescribes. Where amounts appear, they describe what published studies used. Talk to a qualified clinician before acting on anything here.